Social media gurus Gwee and Monseau move on to new jobs

Share this article:
Shwen Gwee
Shwen Gwee
Two of the drug industry's top social media experts, Shwen Gwee and Marc Monseau, are changing jobs.

Shwen Gwee is leaving Vertex to co-lead Edelman's digital health practice.

Gwee, one of the drug industry's top digital and social media gurus, will work out of Edelman's New York office and report to Bruce Hayes, general manager of Edelman's New York healthcare practice, where he'll join former AstraZeneca marketer Gigi Peterkin. Gwee was digital strategy and social media lead at Vertex for several years and also co-founded the Social Health Unconference and the SocialPharmer Network. He's also a member of MM&M's editorial advisory board.

Gwee said on his Med2.0 blog: “While I was able to roll out some cool and interesting digital initiatives during my time at Vertex, my new role at Edelman will allow me to serve the industry in a greater capacity and spread my wings more broadly by challenging me to think across multiple audiences, diseases, and brands/clients.”

Monseau, who has been with J&J for 14 years, including three as director of corporate communication and social media, is leaving the company to open up his own firm, MDM Communications, which "will provide social and digital communication support focusing on healthcare and related industries to help companies become more involved in the social web," he told MM&M.

Gwee and Monseau will hold a live discussion entitled “We've got your social media guidelines right here” at the inaugural MM&M Virtual Summit on May 24. To register for free, click here.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.